Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Milestone Pharmaceuticals (Nasdaq:MIST) announced that management will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq:MIST) announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, in New York.
A live and replay webcast of the 3:00 p.m. ET fireside chat will be available on Milestone's website.
Details
News Market Reaction – MIST
On May 14, the day this news came out, MIST closed 5.23% below the previous close.
Data tracked by StockTitan Argus for the May 14 session.
Key Figures
- Conference date
- May 19, 2026
- H.C. Wainwright 4th Annual BioConnect Investor Conference presentation
- Webcast time
- 3:00pm ET
- Scheduled time for the conference fireside chat webcast
- Replay window
- 90 days
- Duration webcast replay will be available on company website
Historical Context
-
First quarter 2026 financials and CARDAMYST commercial progress with clinical updates.
-
Announcement of Q1 2026 earnings release timing and investor call details.
-
RESET-PSVT Phase 4 real-world registry initiation plan for CARDAMYST nasal spray.
-
Participation in the 25th Annual Needham Virtual Healthcare Conference with webcast.
-
Grant of 123,000 stock options to new hires under inducement plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ to take place on Tuesday, May 19, 2026 in New York.
A live webcast of the fireside chat will be available to conference participants on May 19th at 3:00pm ET. The webcast is available to watch both live and replay for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com. If you are interested in meeting with the Milestone team during the conference, please contact your H.C. Wainwright representative.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com
Media Relations
Rebecca Novak, rnovak@milestonepharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.